TNFRSF17 and plasma cell myeloma: Teclistamab functions as a bispecific antibody engineered to link CD3 expressed on the surface of T‐cells and BCMA expressed on the surface of plasma cells, leading to immunologic cell death of BCMA‐expressing myeloma cells [7].